Cancer Institute A national cancer institute
designated cancer center

Richard Hoppe

Publication Details

  • THE MANAGEMENT OF HODGKINS-DISEASE IN RELAPSE AFTER PRIMARY RADIATION-THERAPY EUROPEAN JOURNAL OF CANCER Hoppe, R. T. 1992; 28A (11): 1920-1922

    Abstract:

    Approximately 20-25% of patients with stage I-II Hodgkin's disease treated initially with irradiation alone will experience a relapse of disease. Restaging at the time of relapse provides a useful prognostic indicator and may help in the selection of salvage therapy. Systemic treatment is indicated in nearly all patients. In the Stanford experience, 109 patients who relapsed were treated with MOPP (or MOPP-like chemotherapy) with or without local irradiation. The actuarial 10-year survival and freedom from second relapse were both 57%. Important prognostic factors included 'relapse stage' (IA vs. II-IIIA vs. I-IIIB or IV) and type of salvage therapy (combined modality vs. chemotherapy alone). Important issues in management of these patients include the selection of chemotherapy agents, whether to incorporate localised irradiation, and the use of even more aggressive salvage treatment programs, such as autologous bone marrow transplantation, in selected patients with a very poor prognosis.

    View details for Web of Science ID A1992JK74700036

    View details for PubMedID 1389536

Stanford Medicine Resources:

Footer Links: